Pds Biotechnology Corporation · NASDAQ:PDSB

Pds Biotechnology — Investor Presentation (February 2026)

22 slides from Pds Biotechnology's investor presentation, Feb 23, 2026

  1. Slide 1: Precision Designed Science for Cancer Patients

    Precision Designed Science for Cancer Patients NASDAQ: PDSB February 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corpo

  3. Slide 3: A Promising Approach to Treating HPV16-Positive Head and Neck Cancers

    A Promising Approach to Treating HPV16-Positive Head and Neck Cancers Targeted immunotherapy with compelling clinical results and regulatory path to accelerated approval CLINICAL INNOVATION 39.3 months median overall survival 12-18 months Keytruda® (pembrolizumab) benchmark in 1L R/M HNSCC 77.4% dis

  4. Slide 4: Lead Program: Seeking to Deliver the First Targeted Immunotherapy for HPV16-Driven Head and Neck Cancers

    Lead Program: Seeking to Deliver the First Targeted Immunotherapy for HPV16-Driven Head and Neck Cancers – Non-EGFR Driven Cancers HPV-16 positive cancers are rapidly increasing in the US and EU, due to: Poor uptake of Human Papillomavirus (HPV) vaccine2,3 Changing sexual behavior4 Unique pathophysi

  5. Slide 5: HPV16+ Patients Have No Targeted Therapies, Leading to Worse Outcomes

    HPV16+ Patients Have No Targeted Therapies, Leading to Worse Outcomes The gap: No approved therapies specifically target HPV16-positive cancers, a distinct patient population with unique unmet needs PUBLISHED EVIDENCE Two head-to-head studies demonstrate that HPV16-positive patients have statistical

  6. Slide 6: The Versamune Platform for Powerful Anti-Tumor T Cells

    The Versamune® Platform for Powerful Anti-Tumor T Cells A lipid nanoparticle trains the immune system to find and destroy cancer8 WHAT IS VERSAMUNE®? Nanoparticles (~200nm) made from a special lipid (R-DOTAP) that the immune system readily absorbs and responds to HOW IT WORKS 1 DELIVER Promotes upta

  7. Slide 7: PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors

    PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors8 Lymph Node Tumor CD4+helper T cell CD8+killer T cell HPV16 E6 & E7 Versamune®Activated CD8+Killer T Cell ImmuneCheckpointInhibitor Versamune® +HPVmix (PDS0101) Targeted CD8+ T CellsTracks to Tumor Dendritic Cell MHC class I MHC c

  8. Slide 8: Pipeline Across Multiple Indications Validated by World-Class Partners

    Pipeline Across Multiple Indications Validated by World-Class Partners Therapy / Treatment Indication P2 P3 Partner Versamune® PDS0101+ pembrolizumab vs. pembrolizumab (VERSATILE-003) HPV16-positive recurrent/metastatic head and neck cancer PDS0101+ chemoRT (IMMUNOCERV) Locally advanced cervical can

  9. Slide 9: VERSATILE-002: PDS0101 + Pembrolizumab in First-Line HPV16-Positive HNSCC

    VERSATILE-002: PDS0101 + Pembrolizumab in First-Line HPV16-Positive HNSCC StudyDesign Single-arm study 31 sites in US and EU 2 Cohorts: ICI Naïve ICI Resistant Key Entry Criteria for ICI Naïve Subjects HPV16-positive R/M HNSCC tumors ≥18 years of age Combined positive score (CPS) ≥1 63% of patients

  10. Slide 10: PDS0101 + Pembrolizumab: mOS of 39.3 Months

    PDS0101 + Pembrolizumab: mOS of 39.3 Months; 12-18 Months mOS is Benchmark with Pembrolizumab and Pembrolizumab + Chemotherapy9 Durable Survival: 11 Patients Surpassed 30 Months mOS = Median Overall Survival No head-to-head studies have been performed

  11. Slide 11: PDS0101: Near or Complete Tumor Shrinkage in Hard-to-Treat Patients

    PDS0101: Near or Complete Tumor Shrinkage in Hard-to-Treat Patients (63% had low CPS 1-19)9 Confirmed Disease Control Rate of 77.4% ORR of 35.8%, Meeting Primary Endpoint 21% of patients had tumor regression of 90-100% *Investigator assessment

  12. Slide 12: PDS0101: Well-Tolerated with a Low Incidence of Adverse Events

    PDS0101: Well-Tolerated with a Low Incidence of Adverse Events Treatment related adverse events (TRAEs) by Grade in ICI naïve and resistant patients n (%) Any Combination TRAE 76 (87.4) Grade 1 40 (46.0) Grade 2 26 (29.9) Grade 3 8 (9.2) Grade 4 1 (1.1)* Grade 5 0 Most common Non-Injection Site Reac

  13. Slide 13: VERSATILE-003: Pivotal Phase in Progress

    VERSATILE-003: Pivotal Phase 3 in Progress Interim Analysis 1 (PFS) Study Start PDS0101 + Pembrolizumab Pembrolizumab Patient Recruitment Patient Recruitment Survival Follow-up Survival Follow-up Key Eligibility Criteria HPV16-positive HNSCC CPS ≥1 ≥18 years of age ECOG 0-1 Primary Endpoints Overall

  14. Slide 14: Well-Positioned in 1L HPV16+ R/M HNSCC in the US and Europe

    Well-Positioned in 1L HPV16+ R/M HNSCC in the US and Europe Median OS Not disclosed 21.3 months 22.6 months 39.3 months 95% CI (23.9, NE) Population All comers HPV-negative HPV16-positive HPV16-positive Administration Convenience IV Q2W until PD or toxicity IV QW (D1, D8, D15) IV Q1W 8X then Q3W for

  15. Slide 15: PDS01ADC: Novel Investigational Tumor Targeting IL-12 Immunocytokine

    PDS01ADC: Novel Investigational Tumor Targeting Interleukin-12 (IL-12) Immunocytokine13 Strong tolerability and potency demonstrated in over 330 patients IL-12 is a powerful NK* and T cell activator that helps fight cancer, but injecting it into the bloodstream causes serious systemic inflammation T

  16. Slide 16: Upcoming Catalysts

    2H 2026 1H 2027 2H 2027 Upcoming Catalysts Enrollment completion PFS data readout (Submission of interim data to FDA) PDS01ADC + HAIP Stage 1 Cholangiocarcinoma2 PDS01ADC + Enzalutamide vs Enzalutamide Biochemically Recurrent Prostate cancer PDS01ADC + Docetaxel Castration Resistant Prostate cancer

  17. Slide 17: Estimated Market (US Only): Significant Commercial Opportunity Across Indications

    Estimated Market (US Only) Significant Commercial Opportunity Across Indications >$6.0B Biochemically recurrent prostate cancer and mCRPC (PDS01ADC)19 ~$2.0B Metastatic colorectal cancer (PDS01ADC)20 >$1.0B Locally advanced HPV16+ HNSCC (PDS0101)14 >$2.0B HPV16+ anal, cervical, penile, vaginal, vulv

  18. Slide 18: Global IP Portfolio Secures Key Commercial Markets

    Global IP Portfolio Secures Key Commercial Markets >12 Patent Families COVERAGE Composition and method claims protecting both platform technology and product candidates PDS0101 EXCLUSIVITY 2042/2043 USA Canada Mexico Israel China Europe Japan Australia 8 Key Markets | North America, Europe, Asia Pac

  19. Slide 19: Multiple Opportunities for Value Creation

    Multiple Opportunities for Value Creation 1 PIPELINE Pipeline Optionality PDS01ADC in Phase 2 trials across multiple indications including: Colon cancer Prostate cancer Others Third-party funded with commercial partnership opportunities 2 PROTECTION Significant IP Estate >12 patent families PDS0101

  20. Slide 20: Thank You

    Thank You NASDAQ: PDSB February 2026

  21. Slide 21: References

    References Harrington, KJ, Burtness B, Greil R, et al. Keytruda With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2022;41:790-802. https://doi.org/10.1200/JCO.21.02508. Damgacioglu H, Sonaw

  22. Slide 22: References (continued)

    References (continued) Minnar CM et al (2024) Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine. Front. Oncol. 13:1321318.doi: 10.3389/fonc.2023.1321318 Triangle Research Group. PDS Proprietary Market Research Report. 2024. Guerendiain D et al; HPV status and HPV16 viral loa

PDS Biotechnology — Investor Presentation (February 2026) on 6ix